HRT Financial’s Standard BioTools LAB Stock Holding History

HRT Financial’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64K	Sell	70,522 -23,260	-25%	-$28.2K	﹤0.01%	3419
2025 Q4	$120K	Buy	+93,782	New	+$126K	﹤0.01%	2758
2024 Q2	–	Sell	-507,417	Closed	-$1.38M	–	2683
2024 Q1	$1.38M	Buy	+507,417	New	+$1.22M	0.01%	735
2023 Q3	–	Sell	-11,877	Closed	-$22K	–	2779
2023 Q2	$22K	Buy	+11,877	New	+$23.4K	﹤0.01%	2090
2022 Q1	–	Sell	-42,758	Closed	-$167K	–	3492
2021 Q4	$167K	Sell	42,758 -90	-0.2%	-$421	﹤0.01%	2600
2021 Q3	$282K	Buy	+42,848	New	+$282K	﹤0.01%	2446
2021 Q2	–	Sell	-10,628	Closed	-$48K	–	3200
2021 Q1	$48K	Sell	10,628 -103,668	-91%	-$569K	﹤0.01%	2548
2020 Q4	$685K	Buy	+114,296	New	+$751K	0.01%	855
2019 Q4	–	Sell	-18,209	Closed	-$84K	–	1415
2019 Q3	$84K	Buy	+18,209	New	+$143K	﹤0.01%	1257

Other funds holding LAB

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HBWM

Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

HRT Financial's LAB Position: Q1 2026 in Review

HRT Financial reduced its Standard BioTools (LAB) stake by 25% in Q1 2026, selling an estimated $28.2K and leaving 70,522 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

HRT Financial first reported a position in LAB in Q3 2019 and has held it in 9 quarters since. The position peaked at $1.38M in Q1 2024. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

HRT Financial held 70,522 shares of Standard BioTools worth $64K as of Q1 2026.
HRT Financial sold 23,260 Standard BioTools shares in Q1 2026, an estimated $28.2K.
Standard BioTools made up ﹤0.01% of HRT Financial's portfolio in Q1 2026, its #3419 holding.
HRT Financial first reported a position in Standard BioTools in Q3 2019 and has held it in 9 quarters since.
HRT Financial's Standard BioTools position peaked at $1.38M in Q1 2024.
155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.